Overview
Medical device company's fiscal Q1 revenue slightly missed analyst expectations
Adjusted EPS for fiscal Q1 beat analyst expectations
Company repurchased $92.5 mln of common stock during the quarter
Outlook
Company projects fiscal 2026 revenue of $4.306 bln to $4.346 bln
CooperCompanies expects fiscal 2026 non-GAAP EPS of $4.58 to $4.66
Company anticipates fiscal 2026 free cash flow of $600 mln to $625 mln
Result Drivers
PREMIUM PORTFOLIO - Revenue growth driven by strength in premium MyDay portfolio and new product launches, including MyDay MiSight
OPERATING MARGINS - Improved operating margins due to disciplined execution and synergies from last year's reorganization
FREE CASH FLOW - Strong free cash flow supported share repurchases, aligning with capital allocation strategy
Company press release: ID:nGNX56NQH2
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Miss*
$1.02 bln
$1.03 bln (15 Analysts)
Q1 Adjusted EPS
Beat
$1.10
$1.03 (16 Analysts)
Q1 EPS
$0.66
Q1 Gross Margin
68.00%
Q1 EBIT Margin
21.00%
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Cooper Companies Inc is $92.50, about 12.8% above its March 4 closing price of $81.98
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)